An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum
Rush Dermatology seeks volunteers with a diagnosis of pyoderma gangrenosum for a clinical trial testing a monoclonal antibody that is given as a subcutaneous injection. All office visits and treatments are provided free of charge.
You may be eligible to participate in this study if you:
- Have an established diagnosis of pyoderma gangrenosum,
- Are currently experiencing an inflammatory episode of pyoderma gangrenosum, with an ulcer developed in the last 30 days at least 3cm2 in size
- Are 18 years of age or older, weight: 88 to 275 pounds
- Have ulcer-related pain
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.